CU20200051A7 - Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 - Google Patents

Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5

Info

Publication number
CU20200051A7
CU20200051A7 CU2020000051A CU20200051A CU20200051A7 CU 20200051 A7 CU20200051 A7 CU 20200051A7 CU 2020000051 A CU2020000051 A CU 2020000051A CU 20200051 A CU20200051 A CU 20200051A CU 20200051 A7 CU20200051 A7 CU 20200051A7
Authority
CU
Cuba
Prior art keywords
bicyclic heterocyclic
prmt5 inhibitors
components replaced
heterocyclic components
replaced
Prior art date
Application number
CU2020000051A
Other languages
English (en)
Other versions
CU24621B1 (es
Inventor
Balasaheb Arjun Gore
Ganesh Bhausaheb Gudade
Anil Kashiram Hajare
Rajender Kumar Kamboj
Chaitanya Prabhakar Kulkarni
Sanjeev Anant Kulkarni
Dipak Raychand Lagad
Prathap Sreedharan Nair
Venkata P Palle
Chetan Sanjay Pawar
Sachin Sethi
Milind Dattatraya Sindkhedkar
Mahadeo Bhaskar Tryambake
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CU20200051A7 publication Critical patent/CU20200051A7/es
Publication of CU24621B1 publication Critical patent/CU24621B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La invención se refiere a compuestos heterocíclicos bicíclicos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas que comprenden al menos un compuesto de fórmula (I).</p>
CU2020000051A 2017-12-13 2018-12-13 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 CU24621B1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201721044886 2017-12-13
IN201821024634 2018-07-02
IN201821040029 2018-10-23
PCT/IB2018/060015 WO2019116302A1 (en) 2017-12-13 2018-12-13 Substituted bicyclic heterocyclic compounds as prmt5 inhibitors

Publications (2)

Publication Number Publication Date
CU20200051A7 true CU20200051A7 (es) 2021-03-11
CU24621B1 CU24621B1 (es) 2022-09-08

Family

ID=65036860

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000051A CU24621B1 (es) 2017-12-13 2018-12-13 Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5

Country Status (30)

Country Link
US (2) US11459330B2 (es)
EP (1) EP3724190B1 (es)
JP (1) JP7282778B2 (es)
KR (1) KR102708147B1 (es)
CN (1) CN111712498B (es)
AU (1) AU2018385664B2 (es)
CA (1) CA3085259A1 (es)
CL (1) CL2020001576A1 (es)
CR (1) CR20200263A (es)
CU (1) CU24621B1 (es)
CY (1) CY1125784T1 (es)
DK (1) DK3724190T3 (es)
ES (1) ES2927860T3 (es)
GE (2) GEP20227359B (es)
HR (1) HRP20221207T1 (es)
HU (1) HUE059945T2 (es)
IL (1) IL274936B2 (es)
LT (1) LT3724190T (es)
MX (1) MX2020006181A (es)
MY (1) MY199124A (es)
PE (1) PE20211444A1 (es)
PH (1) PH12020550881A1 (es)
PL (1) PL3724190T3 (es)
PT (1) PT3724190T (es)
RS (1) RS63623B1 (es)
SG (1) SG11202004934QA (es)
SM (1) SMT202200396T1 (es)
UA (1) UA126349C2 (es)
WO (1) WO2019116302A1 (es)
ZA (1) ZA202003528B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
JP2022522534A (ja) * 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
KR20220016194A (ko) * 2019-05-30 2022-02-08 앤젝스 파마수티컬, 인크. Prmt5 억제제로서의 헤테로시클릭 화합물
CR20220010A (es) 2019-06-10 2022-05-13 Lupin Ltd Inhibidores de prmt5
GEP20247638B (en) * 2019-10-22 2024-07-10 Lupin Ltd Pharmaceutical combination of prmt5 inhibitors
JP2022553376A (ja) * 2019-10-25 2022-12-22 アクセント・セラピューティクス・インコーポレイテッド Ｍｅｔｔｌ３モジュレーター
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
EP4069698A1 (en) * 2019-12-03 2022-10-12 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
CN116568677B (zh) 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
KR20230137368A (ko) 2021-01-19 2023-10-04 루핀 리미티드 암을 치료 및/또는 예방하기 위한 sos1 저해제들의약학적 조합물
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251431A1 (en) 2002-07-22 2004-02-09 Cambridge University Technical Services Ltd. Synthesis of discodermolide
WO2005016878A2 (en) 2003-08-13 2005-02-24 Isis Pharmaceuticals, Inc. METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
JP2012503651A (ja) * 2008-09-26 2012-02-09 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ３−デアザネプラノシン誘導体
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
EP2744333B1 (en) 2011-08-19 2016-10-05 Glaxosmithkline Intellectual Property (No. 2) Limited Fatty acid synthase inhibitors
CN104662018B (zh) * 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
IN2014MN02652A (es) 2012-06-08 2015-08-21 Gilead Sciences Inc
WO2014008223A2 (en) 2012-07-03 2014-01-09 Glaxosmithkline Llc Fatty acid synthase inhibitors
US10118918B2 (en) 2012-12-21 2018-11-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
US9908887B2 (en) * 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Ｐｒｍｔ５インヒビターおよびそれらの使用方法
MX380928B (es) 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
CA2943882A1 (en) 2014-05-22 2015-11-26 F. Hoffmann-La Roche Ag Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
DK3160958T3 (da) 2014-06-25 2021-04-12 Glaxosmithkline Ip Dev Ltd Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
KR102932353B1 (ko) 2015-11-16 2026-02-27 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors

Also Published As

Publication number Publication date
CN111712498A (zh) 2020-09-25
WO2019116302A1 (en) 2019-06-20
PE20211444A1 (es) 2021-08-05
US20210163486A1 (en) 2021-06-03
SG11202004934QA (en) 2020-07-29
CN111712498B (zh) 2023-09-29
US11952380B2 (en) 2024-04-09
HRP20221207T1 (hr) 2022-12-09
JP7282778B2 (ja) 2023-05-29
EP3724190B1 (en) 2022-07-06
KR20200098598A (ko) 2020-08-20
BR112020011746A2 (pt) 2020-11-17
UA126349C2 (uk) 2022-09-21
IL274936A (en) 2020-07-30
ES2927860T3 (es) 2022-11-11
MX2020006181A (es) 2020-09-03
IL274936B1 (en) 2023-05-01
AU2018385664A1 (en) 2020-07-02
CU24621B1 (es) 2022-09-08
US11459330B2 (en) 2022-10-04
RS63623B1 (sr) 2022-10-31
KR102708147B1 (ko) 2024-09-19
JP2021506793A (ja) 2021-02-22
CL2020001576A1 (es) 2020-11-06
EP3724190A1 (en) 2020-10-21
CA3085259A1 (en) 2019-06-20
SMT202200396T1 (it) 2022-11-18
AU2018385664B2 (en) 2022-06-02
ZA202003528B (en) 2022-05-25
CY1125784T1 (el) 2026-02-25
MY199124A (en) 2023-10-17
NZ765656A (en) 2025-02-28
PH12020550881A1 (en) 2021-04-05
US20220267339A1 (en) 2022-08-25
GEP20227359B (en) 2022-03-10
CR20200263A (es) 2020-07-26
DK3724190T3 (da) 2022-10-10
IL274936B2 (en) 2023-09-01
PT3724190T (pt) 2022-10-03
PL3724190T3 (pl) 2022-10-31
HUE059945T2 (hu) 2023-01-28
LT3724190T (lt) 2022-10-10
GEAP202115385A (en) 2021-11-10

Similar Documents

Publication Publication Date Title
CU24621B1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
CU20210009A7 (es) Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3)
CU20180019A7 (es) Derivados de heteroarilo como inhibidores de parp
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
DOP2016000094A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
EA201691302A1 (ru) Новые гетероциклические соединения
CR20150045A (es) Inhibidores de hepatitis c
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
UY35300A (es) Formulación de combinación de dos compuestos antivirales
EA201792021A1 (ru) Ингибитор jak
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
CL2017003340A1 (es) Compuestos inhibidores de serina/treonina-proteína cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y sus usos de los mismos
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
JOP20200030B1 (ar) مركب خماسي الحلقة
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека